By Colin Kellaher
The top executive of Medtronic's cardiovascular portfolio, Sean Salmon, is leaving the medical-technology company.
Medtronic on Wednesday said Skip Kiil, previously senior vice president and president of its cranial and spinal-technologies business, has replaced Salmon as executive vice president and president of the cardiovascular portfolio, which accounted for roughly 37% of the company's $33.5 billion in revenue for its latest fiscal year.
Medtronic said Salmon, who joined the company in 2004 and has been at the helm of the cardiovascular portfolio since the start of 2021, is entitled to severance payments and benefits and will remain an employee until Sept. 2.
The company said Michael Carter, vice president and general manager of its spine business, succeeds Kiil as senior vice president and president of the cranial and spinal-technologies business.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 21, 2025 07:23 ET (11:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.